NCT05786573 - A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

August 31, 2026

Conditions

Warm Autoimmune Hemolytic Anemia

Interventions

DRUG

Obexelimab

Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

DRUG

Obexelimab

Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcγRIIb, resulting in down regulation of B cell activity.

OTHER

Placebo

Trial Locations (7)

National Cheng Kung University Hospital, Tainan City

Hospital Universitario de Burgos, Burgos

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan

Hospital Universitario 12 de Octubre, Madrid

Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk

Plymouth Hospitals NHS Trust, Plymouth

Kent and Canterbury Hospital, Canterbury

All Listed Sponsors

lead

Zenas BioPharma (USA), LLC

INDUSTRY